HC Wainwright Reaffirms “Buy” Rating for Milestone Pharmaceuticals (NASDAQ:MIST)

HC Wainwright reaffirmed their buy rating on shares of Milestone Pharmaceuticals (NASDAQ:MIST) in a report issued on Monday, Benzinga reports. They currently have a $25.00 price objective on the stock.

Separately, Piper Sandler cut their price objective on shares of Milestone Pharmaceuticals from $6.00 to $5.00 and set an overweight rating on the stock in a report on Tuesday, March 5th.

Milestone Pharmaceuticals Price Performance

MIST stock opened at $1.33 on Monday. The company has a current ratio of 22.75, a quick ratio of 22.75 and a debt-to-equity ratio of 1.27. The firm’s 50-day moving average price is $1.55 and its two-hundred day moving average price is $1.67. The stock has a market capitalization of $70.57 million, a price-to-earnings ratio of -1.06 and a beta of 1.63. Milestone Pharmaceuticals has a 12-month low of $1.12 and a 12-month high of $3.86.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings results on Monday, May 13th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.05. As a group, equities analysts predict that Milestone Pharmaceuticals will post -0.79 earnings per share for the current year.

Institutional Investors Weigh In On Milestone Pharmaceuticals

An institutional investor recently raised its position in Milestone Pharmaceuticals stock. BNP Paribas Financial Markets grew its holdings in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 177.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,900 shares of the company’s stock after buying an additional 10,800 shares during the quarter. BNP Paribas Financial Markets’ holdings in Milestone Pharmaceuticals were worth $30,000 at the end of the most recent reporting period. 86.18% of the stock is owned by institutional investors.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.